Molecular Partners AG
OTC:MLLCF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Molecular Partners AG
OTC:MLLCF
|
CH |
|
Puregold Price Club Inc
OTC:PRGLY
|
PH |
|
Select Harvests Ltd
F:H0I
|
AU |
|
Cambridge Cognition Holdings PLC
F:1M7
|
UK |
|
Z
|
ZIGUP PLC
F:21W
|
UK |
|
V
|
Valora Effekten Handel AG
SWB:VEH
|
DE |
|
Chocoladefabriken Lindt & Spruengli AG
F:LSPN
|
CH |
|
T
|
TIS Inc
TSE:3626
|
JP |
|
Pantera Minerals Ltd
ASX:PFE
|
AU |
|
Provaris Energy Ltd
ASX:PV1
|
AU |
Bankruptcy Probability
Molecular Partners AG's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Molecular Partners AG Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CH |
|
Molecular Partners AG
SIX:MOLN
|
126.8m CHF |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
AbbVie Inc
NYSE:ABBV
|
481.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
220.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences, Inc
NASDAQ:GILD
|
182.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
127.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Moderna Inc
NASDAQ:MRNA
|
78.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
76.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
86.9B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Natera Inc
NASDAQ:NTRA
|
56.1B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
45.6B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
40.3B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Molecular Partners AG's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Molecular Partners AG has total debt of 1.8m CHF. This includes both short-term (0 CHF) and long-term (1.8m CHF) debt.
You can find a full breakdown on its Balance Sheet.